Google
ESLA — ESTRELLA IMMUNOPHARMA INC. (Healthcare >> Biotechnology)
ESLA FAQ
What is ESLA's ROE?
ESTRELLA IMMUNOPHARMA INC. reports a Return on Equity (ROE) of 251.43%.
What is ESLA's dividend yield?
ESTRELLA IMMUNOPHARMA INC. offers a dividend yield of 0.00%.
What is ESLA's Deepscope Quality Score?
Deepscope rates ESLA's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ESLA?
Deepscope's AI Timing Score for ESLA is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ESLA belong to?
ESTRELLA IMMUNOPHARMA INC. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 1.14
Price
-0.01
(-0.87%)
Day Change
|
|
|---|
ESLA, the overall quality is not quite good ( Quality = 54) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROA is relatively low.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 95 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.14 |
| PBV / Sector |
-8.49 / 4.63
|
| Earning Per Share | -0.34 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
0.04 M
GREAT
|
| Average 1W Daily Value |
0.06 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:24 |
| Symbol | ESLA |
| Name | ESTRELLA IMMUNOPHARMA INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 43.03 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 44.76 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 5858 Horton Street, EmeryVille, CA, United States, 94608
Phone: 510 318 9098
Website: https://www.estrellabio.com
Sector: Healthcare >> Biotechnology
Description: Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
